David A. Bond

2.4k total citations
50 papers, 501 citations indexed

About

David A. Bond is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, David A. Bond has authored 50 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pathology and Forensic Medicine, 30 papers in Genetics and 24 papers in Oncology. Recurrent topics in David A. Bond's work include Lymphoma Diagnosis and Treatment (39 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Viral-associated cancers and disorders (10 papers). David A. Bond is often cited by papers focused on Lymphoma Diagnosis and Treatment (39 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Viral-associated cancers and disorders (10 papers). David A. Bond collaborates with scholars based in United States, Canada and Australia. David A. Bond's co-authors include Jennifer A. Woyach, Kami J. Maddocks, Samantha Jaglowski, Nathan Denlinger, Mark A. Reiley, Lapo Alinari, Ying Huang, John C. Byrd, Yazeed Sawalha and Seema A. Bhat and has published in prestigious journals such as Journal of Clinical Oncology, Blood and CHEST Journal.

In The Last Decade

David A. Bond

43 papers receiving 486 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David A. Bond United States 12 252 247 199 98 79 50 501
Dima El‐Sharkawi United Kingdom 13 216 0.9× 158 0.6× 140 0.7× 53 0.5× 104 1.3× 64 467
László Váróczy Hungary 13 223 0.9× 127 0.5× 85 0.4× 89 0.9× 56 0.7× 47 425
Matthew T. Howard United States 12 131 0.5× 174 0.7× 102 0.5× 79 0.8× 185 2.3× 55 466
Brian Elliott United States 11 261 1.0× 95 0.4× 359 1.8× 88 0.9× 59 0.7× 32 482
Paola Ghione United States 14 326 1.3× 84 0.3× 254 1.3× 105 1.1× 88 1.1× 64 594
Ryan Jacobs United States 12 190 0.8× 162 0.7× 176 0.9× 113 1.2× 26 0.3× 59 505
Francesca Montanari Italy 12 215 0.9× 70 0.3× 217 1.1× 77 0.8× 78 1.0× 57 407
Wendy Osborne United Kingdom 14 149 0.6× 189 0.8× 342 1.7× 39 0.4× 59 0.7× 46 608
Anna Demurtas Italy 11 191 0.8× 96 0.4× 96 0.5× 64 0.7× 64 0.8× 23 389
Cristina Campidelli Italy 9 190 0.8× 123 0.5× 128 0.6× 59 0.6× 51 0.6× 17 380

Countries citing papers authored by David A. Bond

Since Specialization
Citations

This map shows the geographic impact of David A. Bond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Bond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Bond more than expected).

Fields of papers citing papers by David A. Bond

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Bond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Bond. The network helps show where David A. Bond may publish in the future.

Co-authorship network of co-authors of David A. Bond

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Bond. A scholar is included among the top collaborators of David A. Bond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Bond. David A. Bond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Silberman, Pedro C., Yazeed Sawalha, Beth Christian, et al.. (2024). Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 42(16_suppl). 7033–7033. 2 indexed citations
3.
Wang, Yucai, Melissa C. Larson, Anita Kumar, et al.. (2024). Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7006–7006. 1 indexed citations
4.
Patel, Manish, Michael Tees, Nadia Khan, et al.. (2024). IBCL-147 AC676, an Orally Bioavailable BTK Chimeric Degrader in Patients With B-cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 24. S494–S494. 3 indexed citations
5.
Mei, Matthew, Ni‐Chun Tsai, Joycelynne Palmer, et al.. (2024). Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24(8). 537–542.
6.
7.
Villa, Diego, Aixiang Jiang, Carlo Visco, et al.. (2023). Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Advances. 7(16). 4576–4585. 11 indexed citations
8.
Phillips, Tycel, David A. Bond, Malathi Kandarpa, et al.. (2023). Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Blood Advances. 7(16). 4518–4527. 7 indexed citations
9.
Faisal, Muhammad Salman, Walter Hanel, Timothy Voorhees, et al.. (2023). Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer Medicine. 12(7). 8228–8237. 2 indexed citations
10.
Nalin, Ansel P., Qiuhong Zhao, Timothy Voorhees, et al.. (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia. Frontiers in Oncology. 13. 1264387–1264387. 1 indexed citations
11.
Sigmund, Audrey M., Nathan Denlinger, Patrick Elder, et al.. (2021). Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution. Blood. 138(Supplement 1). 3851–3851. 2 indexed citations
12.
Kittai, Adam S., Cecelia Miller, Ying Huang, et al.. (2021). The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 138(23). 2372–2382. 31 indexed citations
13.
Denlinger, Nathan, David A. Bond, & Samantha Jaglowski. (2021). CAR T-cell therapy for B-cell lymphoma. Current Problems in Cancer. 46(1). 100826–100826. 62 indexed citations
14.
Bond, David A., Ying Huang, James L. Fisher, et al.. (2020). Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 34(12). 3197–3205. 33 indexed citations
15.
Bond, David A. & Kami J. Maddocks. (2020). Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America. 34(5). 903–921. 16 indexed citations
16.
Capers, Quinn, David A. Bond, & Uday Nori. (2020). Bias and Racism Teaching Rounds at an Academic Medical Center. CHEST Journal. 158(6). 2688–2694. 17 indexed citations
17.
Bond, David A. & Jennifer A. Woyach. (2019). Targeting BTK in CLL: Beyond Ibrutinib. Current Hematologic Malignancy Reports. 14(3). 197–205. 101 indexed citations
18.
Bond, David A., et al.. (2018). Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 19(3). e123–e128. 1 indexed citations
19.
Bond, David A. & Lapo Alinari. (2017). Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab. Journal of Blood Medicine. Volume 8. 41–54. 5 indexed citations
20.
Bond, David A., Neil Dunavin, & Gregory A. Otterson. (2015). Mutational Profiling of Second Primary Lung Cancers in Patients Who Have Received Radiation for the Treatment of Hodgkin's Disease. Cancer Investigation. 33(3). 86–88. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dima El‐Sharkawi Breakdown of academic impact, for papers by László Váróczy Breakdown of academic impact, for papers by Matthew T. Howard Breakdown of academic impact, for papers by Brian Elliott Breakdown of academic impact, for papers by Paola Ghione Breakdown of academic impact, for papers by Ryan Jacobs Breakdown of academic impact, for papers by Francesca Montanari Breakdown of academic impact, for papers by Wendy Osborne Breakdown of academic impact, for papers by Anna Demurtas Breakdown of academic impact, for papers by Cristina Campidelli
Rankless by CCL
2026